IRAK4-IN-6

• UNSPSC Description:

  IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma[1].

• Target Antigen:

  IRAK

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/irak4-in-6.html

• Purity:

  99.30

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C(N1CCN([C@@H]2CC[C@@H](NC3=C4C(C=CC(CC#N)=N4)=NC(NC5=CN(C)N=C5)=N3)CC2)CC1)OC

• Molecular Weight:

  504.59

• References & Citations:

  [1]Degorce SL, et al. Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors TargetingMyD88L265P Mutant Diffuse Large B Cell Lymphoma. J Med Chem. 2019 Nov 1.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  2454244-02-9